Publicaciones en colaboración con investigadores/as de Hospital Universitario Son Espases (17)

2024

  1. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

    Breast, Vol. 77

  2. Validation of immunohistochemical overexpression of p16 in the histologic diagnosis of cervical intraepithelial neoplasia grade 2

    Revista Espanola de Patologia, Vol. 57, Núm. 3, pp. 169-175

2022

  1. Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

    International Journal of Infectious Diseases, Vol. 123, pp. 97-103

  2. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. Coexistence of transmural and lateral wavefront progression of myocardial infarction in the human heart

    Revista Espanola de Cardiologia, Vol. 74, Núm. 10, pp. 870-877

  2. Evolution of angiogenic factors in pregnant patients with breast cancer treated with chemotherapy

    Cancers, Vol. 13, Núm. 4, pp. 1-12

  3. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2020

  1. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464

  2. Metoprolol blunts the time-dependent progression of infarct size

    Basic Research in Cardiology, Vol. 115, Núm. 5

  3. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Clinical Cancer Research, Vol. 26, Núm. 22, pp. 5820-5829

  4. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

2018

  1. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

    Annals of Oncology, Vol. 29, Núm. 1, pp. 170-177

1990

  1. PROFILAXIS ANTIBIOTICA CON PIPERACILINA EN LA HISTERECTOMIA VAGINAL. ESTUDIO DE UNA DOSIS FRENTE A TRES

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 8, Núm. 4, pp. 218-221

1989

  1. Human papilloma virus and uterine cervical cancer

    Progresos en Obstetricia y Ginecologia, Vol. 32, Núm. 6, pp. 313-316

  2. LAS CAMPANAS DE SCREENING DE CANCER DE CUELLO DE UTERO Y LA SITUACION DE LOS LABORATORIOS DE CITOLOGIA EN ESPANA

    Citologia, Vol. 11, Núm. 1, pp. 17-21

1985

  1. Second tumor in gynecological cancer

    European Journal of Gynaecological Oncology, Vol. 6, Núm. 3, pp. 199-204